What Should Celgene's Investors Do With Everything Bristol-Meyer Squibb Is Giving Them?The Motley Fool • 06/20/19
Celgene's Long Journey Through Regulatory Filings For Ozanimod Might Finally Pay OffSeeking Alpha • 06/12/19
5 Most Valuable Pipeline Drugs in Development -- and the Stocks Poised to ProfitThe Motley Fool • 06/12/19
The Celgene Merger Looks Secure — So Why Is Bristol Under Pressure?Investors Business Daily • 06/05/19
Argus Questions Logic Behind Bristol-Myers' Proposed Celgene Buy, Steps To SidelinesBenzinga • 05/20/19